Sio Gene Therapies Inc. (NASDAQ:SIOX) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Sio Gene Therapies Inc. (NASDAQ:SIOXGet Rating) have been assigned a consensus rating of “Hold” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $4.20.

A number of analysts have recently weighed in on SIOX shares. SVB Leerink cut shares of Sio Gene Therapies from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $6.00 to $1.00 in a report on Tuesday, February 1st. HC Wainwright lowered shares of Sio Gene Therapies from a “buy” rating to a “sell” rating in a research report on Thursday, April 28th. Zacks Investment Research raised shares of Sio Gene Therapies from a “sell” rating to a “hold” rating in a research report on Thursday, April 14th. Finally, Cantor Fitzgerald lowered shares of Sio Gene Therapies from an “overweight” rating to a “neutral” rating and set a $0.80 target price for the company. in a report on Thursday, April 28th.

Shares of SIOX traded up $0.02 during midday trading on Tuesday, hitting $0.29. The stock had a trading volume of 2,606 shares, compared to its average volume of 565,152. The firm has a market cap of $21.15 million and a PE ratio of -0.34. Sio Gene Therapies has a 1 year low of $0.25 and a 1 year high of $2.95. The stock’s 50 day moving average is $0.58 and its 200 day moving average is $1.06.

Sio Gene Therapies (NASDAQ:SIOXGet Rating) last posted its quarterly earnings results on Friday, February 11th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.09). As a group, sell-side analysts predict that Sio Gene Therapies will post -1.04 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in SIOX. Two Sigma Securities LLC acquired a new stake in Sio Gene Therapies during the 3rd quarter worth $28,000. Marshall Wace LLP acquired a new position in shares of Sio Gene Therapies during the 3rd quarter valued at about $103,000. Morgan Stanley boosted its position in shares of Sio Gene Therapies by 136.5% during the 3rd quarter. Morgan Stanley now owns 68,383 shares of the company’s stock valued at $149,000 after acquiring an additional 39,471 shares during the last quarter. Franklin Resources Inc. acquired a new position in shares of Sio Gene Therapies during the 3rd quarter valued at about $179,000. Finally, State Street Corp raised its holdings in Sio Gene Therapies by 42.9% in the 4th quarter. State Street Corp now owns 157,200 shares of the company’s stock valued at $203,000 after buying an additional 47,200 shares during the period.

About Sio Gene Therapies (Get Rating)

Sio Gene Therapies, Inc, a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis.

See Also

Analyst Recommendations for Sio Gene Therapies (NASDAQ:SIOX)

Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.